Document is current
Any future updates will be listed below
-
Authors
Psalmon, Garance https://orcid.org/0009-0007-3698-0281
Pipier, Angélique https://orcid.org/0000-0002-8481-2860
Barbotte, Manon
Hudson, Robert H. E. https://orcid.org/0000-0002-6530-6479
Neidle, Stephen https://orcid.org/0000-0003-0622-6548
Monchaud, David https://orcid.org/0000-0002-3056-9295
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-22-CE44-0039-01)
Conseil régional de Bourgogne-Franche-Comté (OPE-2024-0046-D103)
- License Information
-
More Information
Article History
Received: 20 August 2025
Accepted: 6 March 2026
First Online: 11 April 2026
Declarations
:
: Not applicable.
: Not applicable.
: S.N. is currently a member of the Scientific Advisory Board of Qualigen Therapeutics Inc. D.M. and the CNRS have licensed TASQs to Merck KGaA for commercialization; D.M. also provides consulting services for Idylle with the commercialization of PhpC.
